IAM
ORMP icon

ICM Asset Management’s Oramed Pharmaceuticals ORMP Stock Holding History

ICM Asset Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-39,000
Closed -$119K – 35
2020
Q1 		$119K Buy
+39,000
New +$171K 0.12% 29

Other funds holding ORMP

JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

ICM Asset Management's ORMP Position: Q2 2020 in Review

ICM Asset Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2020, closing a stake of 39,000 shares — an estimated $119K sold.

ICM Asset Management first reported a position in ORMP in Q1 2020 and held it in 1 quarter. The position peaked at $119K in Q1 2020. 35 funds tracked by Wall St. Rank hold ORMP as of Q2 2020.

  • ICM Asset Management reported no remaining Oramed Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • ICM Asset Management sold 39,000 Oramed Pharmaceuticals shares in Q2 2020, an estimated $119K.
  • ICM Asset Management first reported a position in Oramed Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • ICM Asset Management's Oramed Pharmaceuticals position peaked at $119K in Q1 2020.
  • 35 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2020.

Based on ICM Asset Management's 13F filing for Q2 2020, filed 27 Jul 2020.